Global Peptide Therapeutics Market & Clinical Trials Insight 2028

Reports
Published
Number of pages
1200

For Wire/Bank transfer, contact us at info@pnspharma.com

Electronic Access - Single User License
3600
Electronic Access - Multi User License
6000

Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report Findings:

  • Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028

  • Global Peptide Therapeutics  Clinical Trials Insight by Company, Indication & Phase

  • Peptide Therapeutics in Clinical trials: > 800 Drugs

  • Peptide Therapeutics Commercially Available In Market: > 200 Drugs

  • Global Peptide Therapeutics  Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides

 

Peptides are naturally occurring, small biological molecules made of short chains of amino acids linked by a peptide bond, performing multiple functions within the cell. Peptide drugs have been in use for almost a century now, though initially they were only used to replicate the action of natural hormones for metabolic diseases, for example, the first of this kind that was approved for clinical usage was insulin for the management of diabetes. However, decades of research and development of peptides have resulted in the discovery of peptides that have the ability to penetrate the cell with advanced actions, all of which have shown excellent results for various therapeutic functions.

Till date, more than 200 peptide based therapeutics have gained approval from regulatory bodies. The most common indications for peptides are oncology, endocrinology, and metabolic diseases. Other target areas of peptides that have gained attention include gastroenterology, cardiovascular diseases, dermatology, bone diseases, and sexual dysfunction. The robust response of peptide therapeutics in the market has propelled the further research activities in this domain. Currently, more than 800 clinical trials are ongoing in global peptide therapeutics market which suggests promising future of peptide therapeutics in the forthcoming years.  

The global peptide therapeutics market is both competitive along with being fragmented on account of the presence of several international and also domestic industry players. Such industry players have utilized an assorted innovative strategies for being at the top along with sufficing to the burgeoning requirement of the esteemed clients including geographic expansions, collaborations, joint ventures, new product launches, partnerships, contracts, and much more. For instance, Bicycle Therapeutics has entered into strategic collaboration with Genentech to      discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Further, Fusion Pharmaceuticals also enter into collaboration with Pepscan to discover, novel, peptide-based radiopharmaceuticals for the management of solid tumors.

By therapeutic indication, cancer peptide occupies more than 25% share in the global market. Several peptide based drugs including Firmagon, Eligard, Velcade, Zoladex, Cosmegen, Sandostatin, Mepact, and others have entered the market and have shown robust response rate. More recently, peptide cancer vaccine namely Riavax  have also gained approval in South Korea for the treatment of locally advanced or metastatic pancreatic cancer. The promising sales of these drugs are driving this segment during the forecast period. Furthermore, surge in prevalence of cancer and unmet need of cost effective targeted drugs are also anticipated to propel the growth of cancer peptide drugs during the forecast period.

It is analyzed that the future holds an extensive place for peptides in addressing the greatest of medical challenge due to their capability of being adapted and modified to achieve the desired action. There is immense scope for the development of new peptides with protein fragmentation along with alternative routes of administration and improved oral bioavailability. They will also be used to address the currently undruggable targets in the coming years. Keeping the clinical pipeline in consideration, it is expected that the global peptide therapeutics market will surpass US$ 75 Billion by 2028. In addition to above mentioned factors, rising geriatric population and associated increase in chronic disease will also drive the growth of market.   

The report provides detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide, route of administration, and key therapeutic area. The report also gives insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules. This report forecasts revenue growth at global levels and provides an analysis of the latest trends and opportunities. The major companies mentioned in the report include Amgen, GlaxoSmithKline, NovoNordisk, ImmunoCellular Therapeutics, Lonza, PeptiDream and others.

1. Introduction to Peptide Therapeutics

  1.1 Overview of Peptide Therapeutics

  1.2 Historical Perspective of Peptide Therapeutics

  1.3 Classification Of Anti Cancer Peptides

 

2. Targets for Therapeutic Peptides

  2.1 Signal Transduction Pathways

  2.2 Cell Cycle Regulation

  2.3 Cell Death Pathways

  2.4 Tumor Suppressor Protein

  2.5 Transcription Factors

 

3. Global Peptide Therapeutics Market Overview

 

4. Global Peptide Therapeutics Clinical Trials Overview

  4.1 By Company

  4.2 By Country

  4.3 By Indication

  4.4 By Patient Segment

  4.5 By Phase

 

5. Insulin Clinical Pipeline By Company, Indication & Phase

  5.1 Research

  5.2 Preclinical

  5.3 Phase-I

  5.4 Phase-II

  5.5 Phase-II/III

  5.6 Phase-III

  5.7 Preregistration

  5.8 Registered

  5.9 Marketed

 

6. Glucagon-like Peptides Clinical Pipeline By Company, Indication & Phase

  6.1 Research

  6.2 Preclinical

  6.3 Phase-I

  6.4 Phase-I/II

  6.5 Phase-II

  6.6 Phase-III

  6.7 Preregistration

  6.8 Marketed

 

7. Peptides Clinical Pipeline By Company, Indication & Phase

  7.1 Research

  7.2 Preclinical

  7.3 Clinical Phase Unknown

  7.4 Phase-I

  7.5 Phase-I/II

  7.6 Phase-II

  7.7 Phase-II/III

  7.8 Phase-III

  7.9 Preregistration

  7.12 Registered

  7.11 Marketed

 

8. Cyclic Peptides Clinical Pipeline By Company, Indication & Phase

8.1 Research

8.2 Preclinical

8.3 Clinical Phase Unknown

8.4 Phase-I

8.5 Phase-II

8.6 Phase-III

8.7 Marketed

 

9. Multiple Peptides Clinical Pipeline By Company, Indication & Phase

  9.1 Research

  9.2 Preclinical

  9.3 Phase-I

  9.4 Phase-I/II

  9.5 Phase-II

  9.6 Phase-III

  9.7 Preregistration

  9.8 Registered

  9.9 Marketed

 

10. Glycopeptides Clinical Pipeline By Company, Indication & Phase

  10.1 Research

  10.2 Preclinical

  10.3 Phase-I

  10.4 Phase-I/II

  10.5 Preregistration

  10.6 Marketed

 

11. Oligopeptides Clinical Pipeline By Company, Indication & Phase

  11.1 Preclinical

  11.2 Phase-I/II

  11.3 Phase-II

  11.4 Phase-II/III

  11.5 Phase-III

  11.6 Registered

  11.7 Marketed

 

12. Lipopeptides Clinical Pipeline By Company, Indication & Phase

  12.1 Research

  12.2 Phase-II

  12.3 Marketed

 

13. Dipeptides Clinical Pipeline By Company, Indication & Phase

  13.1 Research

  13.2 Phase-I

  13.3 Phase-II

  13.4 Phase-III

  13.5 Registered

  13.6 Marketed

 

14. Opioid Peptides Clinical Pipeline By Company, Indication & Phase

  14.1 Research

  14.2 Preclinical

  14.3 Phase-I/II

  14.4 Preregistration

  14.5 Registered

  14.6 Marketed

 

15. Depsipeptides Clinical Pipeline By Company, Indication & Phase

  15.1 Preclinical

  15.2 Phase-II

  15.3 Registered

  15.4 Marketed

 

16. Neuropeptides Clinical Pipeline By Company, Indication & Phase

  16.1 Research

  16.2 Preclinical

  16.3 Phase-I/II

  16.4 Phase-II

  16.5 Marketed

 

17. Natriuretic Peptides Clinical Pipeline By Company, Indication & Phase

  17.1 Phase-II

  17.2 Marketed

 

18. Bicyclic Peptides Clinical Pipeline By Company, Indication & Phase

  18.1 Preclinical

 

19. Competitive Landscape

  19.1 Amgen

  19.2 Amylin Pharmaceuticals

  19.3 Apitope Technology

  19.4 BioPartners

 19.5 BiondVax Pharmaceuticals Ltd

  19.6 Boehringer Ingelheim

  19.7 Circassia

  19.8 Corden Pharma (Peptisyntha)

  19.9 Eli Lily

  19.10 Galena Biopharmaceuticals

  19.11 GlaxoSmithKline

  19.12 Hyperion Therapeutics

  19.13 ImmunoCellular Therapeutics

  19.14 Ipsen

  19.15 Lonza

  19.16 Merck

  19.17 NovoNordisk

  19.18 Par Pharmaceuticals

  19.19 PeptiDream

  19.20 Roche

  19.21 Sanofi

  19.22 Tarix Pharmaceuticals

Figure 1-1: Classification of Anti-Cancer Peptides

 

Figure 2-1: Therapeutic Peptides Based on Their Biological Targets

Figure 2-2: MAPK Signaling Pathways

Figure 2-3: Cell Cycle in Eukaryotic

Figure 2-4: Cell Death Pathways

Figure 2-5: Features of Bcl-2 Family Proteins Including Anti-Apoptotic & Pro-Apoptotic

 

Figure 3-1: Global – Peptide Therapeutic Market (US$ Billion), 2020 - 2028

Figure 3-2: Global – Total Peptide Therapeutic Market Size vs. Cancer Peptide Therapeutic Market (US$ Billion), 2021

Figure 3-3: Global – Cancer Peptide Market Share in Total Peptide Market (%), 2021

Figure 3-4: Global – Cancer Peptide Drugs Market Size (US$ Billion), 2020 - 2028

 

Figure 4-1: Global - Peptide Drug Clinical Pipeline by Company (Number of Drugs), 2022 till 2028

Figure 4-2: Global - Peptide Drug Clinical Pipeline by Country (Number of Drugs), 2022 till 2028

Figure 4-3: Global - Peptide Drug Clinical Pipeline by Indication (Number of Drugs), 2022 till 2028

Figure 4-4: Global - Peptide Drug Clinical Pipeline by Patient Segment (Number of Drugs), 2022 till 2028

Figure 4-5: Global - Peptide Drug Clinical Pipeline by Phase (Number of Drugs), 2022 till 2028